BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

RBC Life Sciences, Inc. Reports Third Quarter Results


11/9/2011 11:45:30 AM

IRVING, Texas,Nov. 9, 2011 /PRNewswire/ -- RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, wound care and pain management products, today reported an increase in consolidated net sales of 15% for the third quarter of 2011. Net sales for the quarter ended September 30, 2011 were $7.1 million compared to net sales of $6.1 million for the same quarter in 2010. For the third quarter of 2011, the Company also reported a net loss of $290,000, or $0.01 per share, compared to net earnings of $133,000, or $0.01 per share, for the same quarter last year. Net sales were $21.1 million and $20.9 million for the nine months ended September 30, 2011 and 2010, respectively, while the net loss for the nine months ended September 30, 2011 was $129,000, or $0.01 per share, compared to net earnings of $517,000, or $0.02 per share the comparable period in 2010.

"Net sales in our Associate network channel have been very positive this year growing 54% during the first nine months of 2011. We continue to see strong sales results for our new product, Stem-Kine, and new Associate growth in excess of 100%," said RBC Life Sciences President and CEO, Clinton H. Howard. "The net loss in the third quarter resulted mainly from investments we made in a new branch office in Taiwan, which opened October 1, 2011, a Company-sponsored leadership event for the top achievers in our Associate network and expansion of our Medical Products sales force."

Stem-Kine is a dietary supplement that has been shown in published human clinical studies to nutritionally enable bone marrow and other stem-cell-producing tissues to increase their production of stem cells, which form the natural repair and renewal system of the body. The Company distributes Stem-Kine under an exclusive license agreement that covers the U.S. and 41 other countries.

About RBC Life Sciences

Through wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's website at www.rbclifesciences.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES